One-Shot wonder? huge study tests single HPV vaccine dose

NCT ID NCT03180034

Ongoing Prevention Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This large study of nearly 28,000 girls aged 12-16 tests whether a single dose of HPV vaccine works as well as the standard two doses to prevent persistent infection with the virus types that cause most cervical cancers. If one dose is enough, it could lower costs and simplify vaccination, especially in countries with high cervical cancer rates. The study is ongoing and results will show if a single shot provides lasting protection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Human papillomavirus vaccine (Cervarix or Gardasil-9)
What this could lead to: If one dose works, it could make HPV vaccination cheaper and easier, helping more people get protected against cervical cancer.
What could go wrong: This is an early-stage comparison; one dose may prove less effective than two, and long-term protection is still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMAVIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical carcinoma human papilloma virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUMAN PAPILLOMAVIRUS INFECTION HUMAN PAPILLOMAVIRUS-RELATED CERVICAL CARCINOMA

Contacts and locations

Locations

Agencia Costarricense de Investigaciones Biomédicas (ACIB)

Liberia, Guanacaste Province, 50101, Costa Rica

More trials for these conditions

Other studies related to the condition(s) this trial covers.